Jiangao Zhu

Changsha Medical University, Ch’ang-sha-shih, Hunan, China

Are you Jiangao Zhu?

Claim your profile

Publications (2)2.19 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Two anti-idiotypic monoclonal antibodies (Ab2), designated 2H4 and 5D3, against two antitumor antibodies Ab1 (FC2 and HNL5) that recognize nasopharyngeal carcinoma (NPC) associated antigen were generated. They could substitute NPC antigen to induce humoral and cellular immune response against NPC cells in syngeneic mice. Nineteen patients with NPC at stage IV were chosen for active immunotherapy. They were treated with aluminum hydroxide-precipitated Ab2 2H4 or 5D3 accompanying radiotherapy. None of the immunization of anti-idiotypic monoclonal antibody (mAb) was associated with toxicity or allergies reactions. Nine patients with radiotherapy alone served as control. Both anti-anti-idiotypic antibodies (Ab3) and anti-NPC antibodies (Ab1') were increased and human anti-mouse Ig antibodies (HAMA) occurred in nineteen patients of the experimental group; whereas the levels of Ab1' did not rise in the control group. Serum IL-2, IFN-gamma, and TNF-alpha levels were increased in most patients in the experimental group, while in the control group, there were no differences of Ab1' and cytokine level between pretherapy and posttherapy. In addition, IL-2 mRNA expression in peripheral blood mononuclear cells (PBMC) of NPC patients was closely related to serum IL-2 (r = +0.8829) by in situ hybridization. Therefore, mouse anti-idiotypic antibodies 2H4 and 5D3 are safe for active immunotherapy and might enhance humoral and/or cellular immunity of NPC patients receiving radiotherapy.
    Cancer Biotherapy and Radiopharmaceuticals 01/2003; 17(6):673-9. · 1.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An anti-idiotypic monoclonal antibody 2A9 (Ab2) was prepared, which mimicked the nasopharynegeal carcinoma (NPC) cell antigen defined by anti-NPC McAb Fcl. The abilities of 2A9’s inducing humoral and cellular immunity against NPC cell antigen were studied in syngeneic mice by inducing anti-Ab2 sera (Ab3) and delayed-type hypersensitivity. Two periods of phase 1 clinical trials were carried out, stage IV NPC patients receiving radiotherapy were chosen. Human anti-mouse antibodies (HAMA), anti-anti-idiotypic antibodies (Ab3), and anti-NPC cell antibodies (Abl′) were detected by ELISA. TNF-α,IL-2, IFN-γ levels in sera were determined by ELISA Kits. IL-2 mRNA expression in peripheral blood mononuclear cells (PBMC) were shown byin situ hybridization. The results showed that 2A9 was safe in applying on NPC patients and induced some humoral and/or cellular immune responses.
    Chinese Journal of Cancer Research 01/1997; 9(2):127-132. · 0.45 Impact Factor

Publication Stats

2 Citations
2.19 Total Impact Points

Institutions

  • 1997
    • Changsha Medical University
      Ch’ang-sha-shih, Hunan, China